Leading quantitative pharmacology for decisive drug development
Clear thinking. Decisive action. Meaningful impact.
Non-Clinical PK/PD & Dose Justification
Quantitative interpretation of non-clinical data to define exposure–response
PK/PD model development and interpretation
Integration of biomarker and exposure data
Characterisation of dose–response relationships
Design and refinement of non-clinical studies
Clear quantitative rationale for dosing decisions and development strategy
Translational Modelling
Structuring non-clinical evidence into clinically meaningful predictions
First-in-human dose prediction
Cross-species translation and scaling approaches
Mechanistic and semi-mechanistic modelling
Scenario simulation for development decisions
Improved confidence in early clinical assumptions and clinical study design
Clinical Pharmacology & Development Support
Interpretation of clinical data to inform dosing and development decisions
Interpretation and modelling of early clinical PK data (SAD/MAD and beyond)
Dose escalation strategy and exposure characterisation
Assessment of dose proportionality, variability, and covariate effects
Input into clinical study design and analysis considerations
Integration of emerging pharmacodynamic and biomarker signals
Clear, quantitative understanding of exposure and dose behaviour to support safe, informed escalation and development decisions
A different way of working
BeMath was created to provide a more direct, flexible, and engaged approach to quantitative pharmacology.
Work is delivered with senior-level focus, without unnecessary layers, and with a pragmatic approach that prioritises what matters most for decision-making.
The aim is simple: clear thinking, high-quality work, and meaningful impact on development decisions.
Areas of Expertise
-
Oncology
(and other therapeutic areas)
-
Small Molecules & Biologics
-
Bispecific Antibodies & ADCs
-
Translational Pharmacology
(incl. Animal Rule applications)